Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()

A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most men with CRPC have intact androgen receptor (AR) signaling. As previous work supports negative regulation of MET by A...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yuanyuan, Feng, Felix Y., Wang, Yugang, Cao, Xuhong, Han, Sumin, Wilder-Romans, Kari, Navone, Nora M., Logothetis, Christopher, Taichman, Russell S., Keller, Evan T., Palapattu, Ganesh S., Alva, Ajjai S., Smith, David C., Tomlins, Scott A., Chinnaiyan, Arul M., Morgan, Todd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735600/
https://www.ncbi.nlm.nih.gov/pubmed/26806347
http://dx.doi.org/10.1016/j.neo.2015.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735600/
https://www.ncbi.nlm.nih.gov/pubmed/26806347
http://dx.doi.org/10.1016/j.neo.2015.11.009

Ejemplares similares